{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T17:23:36Z","timestamp":1696353816720},"reference-count":0,"publisher":"Hogrefe Publishing Group","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Praxis"],"published-print":{"date-parts":[[2015,10]]},"abstract":"<jats:p> Zusammenfassung. Nalmefen (Selincro\u00ae) ist ein selektiver Opioidrezeptorantagonist, der im April 2014 in der Schweiz zur Reduktion des Alkoholkonsums bei Patienten auf einem hohen Risikoniveau zugelassen wurde. Eine systematische Suche in der globalen WHO Datenbank der Pharmacovigilance VigiBase\u2122 ergab weltweit 200 Meldungen unerw\u00fcnschter Arzneimittelwirkungen unter Nalmefen im Zeitraum vom 7. M\u00e4rz 1997 bis 1. M\u00e4rz 2015. In 21 F\u00e4llen (10,5%) wurde Nalmefen zusammen mit einem Opioid verabreicht, was zu Entzugssymptomen f\u00fchrte. Bisher wurden dem regionalen Pharmacovigilance Zentrum Z\u00fcrich vier F\u00e4lle gemeldet, in denen Nalmefen mit Opioiden kombiniert wurde. Diese Arzneimittelkombination sollte strikt vermieden werden. <\/jats:p>","DOI":"10.1024\/1661-8157\/a002160","type":"journal-article","created":{"date-parts":[[2015,10,14]],"date-time":"2015-10-14T12:25:11Z","timestamp":1444825511000},"page":"1129-1134","source":"Crossref","is-referenced-by-count":5,"title":["Nalmefen und Opioid-Entzugssyndrom: systematische Analyse der globalen PharmacovigilanceDatenbank"],"prefix":"10.1024","volume":"104","author":[{"given":"Hendrike","family":"Dahmke","sequence":"first","affiliation":[{"name":"Regionales Pharmacovigilance Zentrum, Klinik f\u00fcr Klinische Pharmakologie und Toxikologie, Universit\u00e4tsspital Z\u00fcrich und Universit\u00e4t Z\u00fcrich"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo","family":"Kupferschmidt","sequence":"additional","affiliation":[{"name":"Regionales Pharmacovigilance Zentrum, Klinik f\u00fcr Klinische Pharmakologie und Toxikologie, Universit\u00e4tsspital Z\u00fcrich und Universit\u00e4t Z\u00fcrich"},{"name":"Tox Info Suisse, Assoziiertes Institut der Universit\u00e4t Z\u00fcrich"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd A.","family":"Kullak-Ublick","sequence":"additional","affiliation":[{"name":"Regionales Pharmacovigilance Zentrum, Klinik f\u00fcr Klinische Pharmakologie und Toxikologie, Universit\u00e4tsspital Z\u00fcrich und Universit\u00e4t Z\u00fcrich"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Weiler","sequence":"additional","affiliation":[{"name":"Regionales Pharmacovigilance Zentrum, Klinik f\u00fcr Klinische Pharmakologie und Toxikologie, Universit\u00e4tsspital Z\u00fcrich und Universit\u00e4t Z\u00fcrich"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"101","container-title":["Praxis"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/econtent.hogrefe.com\/doi\/pdf\/10.1024\/1661-8157\/a002160","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T07:30:58Z","timestamp":1615966258000},"score":1,"resource":{"primary":{"URL":"https:\/\/econtent.hogrefe.com\/doi\/10.1024\/1661-8157\/a002160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":0,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["10.1024\/1661-8157\/a002160"],"URL":"https:\/\/doi.org\/10.1024\/1661-8157\/a002160","relation":{},"ISSN":["1661-8157","1661-8165"],"issn-type":[{"value":"1661-8157","type":"print"},{"value":"1661-8165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}